Arca
Skip to content
Tools
Tools

PLAT: Tissue-type plasminogen activator

Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen.

  • Drugs that act on it: 8
  • Approved: 4
  • In phases 1 to 3: 4
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on PLAT, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Protein or peptide 7

Approved4

  • Alteplase
  • Tenecteplase
  • Reteplase
  • Aminocaproic acid

Phase 31

  • Monteplase

Phase 23

  • Duteplase
  • Lanoteplase
  • Pamiteplase

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 7 of 8 act as: Tissue-type plasminogen activator exogenous protein; the rest name their own mechanism.
    AlteplaseApprovedRocheProtein or peptideExogenous protein105
    TenecteplaseApprovedRocheProtein or peptideExogenous protein82
    ReteplaseApprovedEKR TherapeuticsProtein or peptideExogenous protein6
    Aminocaproic acidApprovedHikma PharmaceuticalsSmall moleculeInhibitorTissue-type plasminogen activator inhibitor4
    MonteplasePhase 3—Protein or peptideExogenous protein0
    DuteplasePhase 2—Protein or peptideExogenous protein0
    LanoteplasePhase 2—Protein or peptideExogenous protein0
    PamiteplasePhase 2—Protein or peptideExogenous protein0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 20 in all, from ClinicalTrials.gov.
    Dose Reduced Alteplase in Managing Intrapleural SepsisAlteplasePhase 3Not yet recruitingVanderbilt University Medical CenterNov 17, 2026
    Pneumatic Displacement With Anti-VEGF and Concomitant rtPA for PCV-related Submacular HemorrhageAlteplasePhase 4Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineNov 17, 2026
    Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine HemorrhageAlteplase, TenecteplaseNot applicableRecruitingBeijing Tiantan HospitalNov 16, 2026
    Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 HoursAlteplase, TenecteplasePhase 3Not yet recruitingThe First Affiliated Hospital of University of Science and Technology of ChinaNov 12, 2026
    Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk FeaturesAlteplasePhase 3Not yet recruitingChina National Center for Cardiovascular DiseasesNov 4, 2026
    Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 HoursAlteplase, TenecteplasePhase 3Not yet recruitingFujian Medical University Union HospitalNov 3, 2026
    INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632Alteplase, TenecteplasePhase 3Not yet recruitingUniversity of CalgaryOct 30, 2026
    Tenecteplase in Acute Ischemic Stroke Under Different Transfer ModelsAlteplase, Tenecteplase—Not yet recruitingFujian Medical University Union HospitalOct 27, 2026
    A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic StrokeTenecteplasePhase 2 / Phase 3Not yet recruitingXinqiao Hospital of ChongqingSep 25, 2026
    Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular EventsReteplase, TenecteplasePhase 3RecruitingYongjun WangAug 5, 2026
    TeleStroke-Guided Thrombolysis for Acute Ischemic Stroke in OmanTenecteplasePhase 4Not yet recruitingOman Ministry of HealthJul 22, 2026
    Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated CoagulationAminocaproic acidPhase 4Not yet recruitingNYU Langone HealthJun 12, 2026
    Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic StrokeReteplaseNot applicableNot yet recruitingChina-Japan Union HospitalMar 19, 2026
    Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 MonthsReteplasePhase 3Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineFeb 24, 2025
    Intravenous Thrombolysis in Acute Ischemic Stroke with Active CancerReteplasePhase 3Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineFeb 24, 2025
    Intravenous Thrombolysis and NOACReteplasePhase 3RecruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineDec 27, 2024
    Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac SurgeryAminocaproic acidNot applicableRecruitingSaint Petersburg State University, RussiaJul 9, 2024
    Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling DeficitsReteplasePhase 4Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineNov 2, 2023
    Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Aminocaproic acid—RecruitingDuke UniversityFeb 20, 2020
    Efficacy of Amicar for Children Having Craniofacial SurgeryAminocaproic acidPhase 2Active, not recruitingChildren's National Research InstituteSep 3, 2014

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Stroke disorder
    0.58
    Recurrent thrombophlebitis
    0.50
    Congestive heart failure
    0.38
    Hemorrhagic disease
    0.37
    Eye disorder
    0.37

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1873, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P00750, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.